Comparison / GHRH-axis secretagogues
Sermorelin vs CJC-1295: Native GHRH(1-29) Against a Long-Acting Analog
Two panels, one axis: the short-lived native fragment, and the half-life-extension chemistry built to outlast it.
The short version
Sermorelin vs CJC-1295 is, at heart, a half-life story. Both are GHRH-axis secretagogues — both tell the pituitary to release the body's own growth hormone. Sermorelin is the plain native fragment: it clears from the blood in about 10-12 minutes [3]. CJC-1295 is an engineered relative built to last far longer, using chemistry that grabs onto a blood protein so it isn't cleared as fast [10]. So the comparison is not "which is stronger" but "native and brief" versus "modified and long-acting." This page lays both side by side and cites the pharmacokinetics to source.
Native GHRH(1-29): short by design
Sermorelin is the unmodified active fragment of GHRH. Its pharmacokinetics are well characterized: in 30 healthy men, intravenous GHRH(1-29)NH2 elicited significant GH release at doses as low as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg [3]. The plasma half-life is on the order of 10-12 minutes — the peptide is rapidly eliminated — yet a single dose keeps serum GH elevated for roughly 3 hours [3]. Intranasal bioavailability in the same work was only 3-5% [3], which is why subcutaneous injection is the route studied and why oral and sublingual formulations draw consistent criticism in research-user communities.
That brevity is the whole point of comparison. The native peptide does its job and clears — a clean, feedback-respecting pulse, but a short one.
Why CJC-1295 exists: half-life extension
CJC-1295 is what happens when chemists set out to keep a GHRH signal in circulation. The native peptide's short half-life [3] motivated longer-acting analogs through two strategies catalogued in the GRF-analogue literature: stabilizing substitutions such as D-Ala2 to resist enzymatic breakdown, and conjugation chemistry to slow clearance [10]. A review of PEGylation of GHRH (GRF) analogues describes attaching polyethylene-glycol chains to prolong action; the DAC (Drug Affinity Complex) approach behind CJC-1295 instead uses a maleimide group that binds serum albumin, tethering the peptide to a long-lived carrier protein [10].
The trade is design, not magnitude. Sermorelin reproduces the brief native pulse; CJC-1295's chemistry extends GHRH-axis exposure across a longer window. Both remain GHRH-receptor agonists acting on the same somatotroph pathway [11].
Reading the two side by side
Set against sermorelin's short half-life, the contrast is clean. Native GHRH(1-29) clears in ~10-12 minutes and elevates GH for ~3 hours per dose [3] — a short, repeatable pulse that leans on bedtime timing to align with the body's largest natural nocturnal GH burst. The DAC-extended analog is engineered for a far longer duration of action from the same receptor mechanism [10][11].
For the receptor-level mechanism both share, see the published human research. For the doses used to study each in the literature, see doses used in research. The comparison ends where the evidence does: the native peptide's PK is precisely measured [3]; long-term human efficacy and safety data for adult use of either remain limited.